CA2582552A1 - Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer - Google Patents

Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer Download PDF

Info

Publication number
CA2582552A1
CA2582552A1 CA002582552A CA2582552A CA2582552A1 CA 2582552 A1 CA2582552 A1 CA 2582552A1 CA 002582552 A CA002582552 A CA 002582552A CA 2582552 A CA2582552 A CA 2582552A CA 2582552 A1 CA2582552 A1 CA 2582552A1
Authority
CA
Canada
Prior art keywords
igf
cancer
receptor
receptor ligand
contacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002582552A
Other languages
English (en)
French (fr)
Inventor
Hugh Mctavish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGF Oncology LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2582552A1 publication Critical patent/CA2582552A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA002582552A 2004-10-21 2005-10-21 Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer Abandoned CA2582552A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62079404P 2004-10-21 2004-10-21
US60/620,794 2004-10-21
PCT/US2005/037739 WO2006047214A2 (en) 2004-10-21 2005-10-21 Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer

Publications (1)

Publication Number Publication Date
CA2582552A1 true CA2582552A1 (en) 2006-05-04

Family

ID=36228252

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002582552A Abandoned CA2582552A1 (en) 2004-10-21 2005-10-21 Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer

Country Status (5)

Country Link
US (2) US8017102B2 (https=)
EP (1) EP1812082B1 (https=)
JP (1) JP2008517917A (https=)
CA (1) CA2582552A1 (https=)
WO (1) WO2006047214A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047214A2 (en) * 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
US7749966B2 (en) * 2006-12-21 2010-07-06 Boston Biomedical Research Institute Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity
CA2930681C (en) 2007-04-09 2019-10-15 The Board Of Trustees Of The University Of Arkansas Fusion protein of collagen-binding domain and parathyroid hormone
JP5264725B2 (ja) 2007-06-29 2013-08-14 第一三共株式会社 ペプチド性薬物の粘膜吸収促進剤を含有する粘膜投与用組成物、及びその投与方法
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
EP2376099A4 (en) * 2008-12-19 2012-04-25 Univ Indiana Res & Tech Corp INSULIN AGAIN YL-BASED GROWTH FACTORS WITH HIGH ACTIVITY AT THE INSULIN RECEPTOR
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
EP2585102B1 (en) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
US9579273B2 (en) 2011-12-14 2017-02-28 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
CA2936675C (en) 2014-01-12 2023-06-27 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
CN106573073B (zh) 2014-06-13 2021-09-28 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
CN108367048B (zh) 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
EP3595699A4 (en) * 2017-03-16 2020-12-23 Blaze Bioscience, Inc. PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
CN117442747A (zh) 2017-05-21 2024-01-26 Igf肿瘤公司 胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008715A1 (en) 1987-05-11 1988-11-17 Procyte Corporation Method of tumor inhibition in warm-blooded animals
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
DE59101382D1 (de) * 1990-12-31 1994-05-19 Fatzer Ag Romanshorn Vorrichtung zur Stossdämpfung für ein auf Zug beanspruchtes Seil für Steinschlag- und Schneeverbauungen.
ATE124742T1 (de) * 1992-02-18 1995-07-15 Fatzer Ag Spiraldrahtseilanker, insbesondere zur verankerung von steinschlag- und lawinenschutzsystemen.
WO1993021939A1 (en) 1992-04-27 1993-11-11 New England Deaconess Hospital Corporation Method of treating cancer
US5395105A (en) * 1993-11-05 1995-03-07 Thommen, Jr.; Robert A. Safety net system
CA2145829C (en) * 1994-04-08 2003-03-18 Bernhard Eicher Method and apparatus for producing a retaining net
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US5961099A (en) * 1998-01-23 1999-10-05 Brugg Cable Products, Inc. Safety net system for debris and mud slides
CH692921A5 (de) * 1998-02-25 2002-12-13 Fatzer Ag Drahtgeflecht vorzugsweise als Steinschlagschutz oder für die Sicherung einer Erdoberflächenschicht.
US7173005B2 (en) * 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US6050038A (en) * 1998-09-11 2000-04-18 Fey; James M. Foundation system for supporting a superstructure
JP4751556B2 (ja) * 2000-02-28 2011-08-17 ジーンシーグス， インコーポレイテッド ナノカプセルカプセル化システムおよび方法
EP1383793B1 (en) * 2000-03-29 2011-10-19 DGI BioTechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
IL153288A0 (en) 2000-06-07 2003-07-06 Applied Research Systems Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis
AU2001284906A1 (en) * 2000-08-24 2002-03-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CH695104A5 (de) * 2000-11-13 2005-12-15 Fatzer Ag Auffangnetz insbesondere für Steinschlagverbauungen
WO2002072780A2 (en) * 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
US7771727B2 (en) 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US20040142381A1 (en) * 2002-07-31 2004-07-22 Hubbard Stevan R. Methods for designing IGF1 receptor modulators for therapeutics
US20060246036A1 (en) 2002-09-06 2006-11-02 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
US20030138430A1 (en) * 2002-09-20 2003-07-24 Stimmel Julie Beth Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
CA2542834C (en) * 2003-10-21 2012-04-24 Igf Oncology, Llc Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents
WO2006047214A2 (en) * 2004-10-21 2006-05-04 Igf Oncology, Llc Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer

Also Published As

Publication number Publication date
US20110301340A1 (en) 2011-12-08
US8017102B2 (en) 2011-09-13
WO2006047214A3 (en) 2006-06-15
EP1812082B1 (en) 2013-08-14
JP2008517917A (ja) 2008-05-29
US8920777B2 (en) 2014-12-30
WO2006047214A2 (en) 2006-05-04
EP1812082A4 (en) 2010-06-02
US20070224119A1 (en) 2007-09-27
EP1812082A2 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
US8017102B2 (en) Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer
EP0259904B1 (en) Advanced anticancer therapy and cytotoxic medicaments for its implementation
US5112954A (en) Method of enhancing the effect of cytotoxic agents
Aboud-Pirak et al. Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor.
US12296018B2 (en) Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
Russell et al. Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies
EP1237584B1 (en) Receptor binding conjugates
Andersson et al. Binding of epidermal growth factor‐dextran conjugates to cultured glioma cells
US5728369A (en) Radioactive phosphorus labeling of proteins for targeted radiotherapy
US20020164302A1 (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
Rowlinson-Busza et al. Targeted delivery of biologic and other antineoplastic agents
Sundberg et al. Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran
Carlsson et al. Conjugate chemistry and cellular processing of EGF-dextran
Hauck et al. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia
Boven et al. Monoclonal antibodies in cancer treatment: where do we stand after 10 years?
JPH05500953A (ja) 免疫共役体およびその代謝物の非標的保持量を減少させる方法
Holmberg et al. Labeling of polypeptides with technetium-99m using a dextran spacer
Zhao et al. Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clinical trials.
US20040219097A1 (en) Composition useful for the diagnosis, imaging and treatment of tumors
CA2219961C (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
US20040219098A1 (en) Methods for the treatment of tumors
Mokotoff et al. Targeting growth factor receptors with bispecific molecules
US20040220390A1 (en) Composition useful for the treatment of tumors
Perälä et al. Biodistribution in normal mice of an111in-labelled prostatic acid phosphatase-specific antibody and its F (ab′) 2 fragments derivatized site-specifically or via bicyclic diethyl enetriaminepentaacetic acid anhydride
Russell-Jones Cellular Delivery Systems

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141117